SA
PTCT icon

Sicart Associates’s PTC Therapeutics PTCT Stock Holding History

Sicart Associates’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+2,745
New +$198K 0.05% 72
2026
Q1 		– Sell
-2,745
Closed -$209K – 77
2025
Q4 		$209K Buy
+2,745
New +$199K 0.06% 73
2023
Q3 		– Sell
-5,100
Closed -$207K – 68
2023
Q2 		$207K Sell
5,100
-3,075
-38% -$150K 0.08% 63
2023
Q1 		$396K Hold
8,175
– – 0.15% 53
2022
Q4 		$312K Hold
8,175
– – 0.11% 63
2022
Q3 		$410K Hold
8,175
– – 0.15% 56
2022
Q2 		$327K Hold
8,175
– – 0.1% 60
2022
Q1 		$305K Hold
8,175
– – 0.08% 72
2021
Q4 		$328K Hold
8,175
– – 0.09% 78
2021
Q3 		$304K Hold
8,175
– – 0.08% 86
2021
Q2 		$346K Hold
8,175
– – 0.08% 86
2021
Q1 		$387K Sell
8,175
-25
-0.3% -$1.49K 0.1% 76
2020
Q4 		$500K Hold
8,200
– – 0.12% 73
2020
Q3 		$383K Hold
8,200
– – 0.11% 76
2020
Q2 		$416K Hold
8,200
– – 0.13% 72
2020
Q1 		$366K Sell
8,200
-525
-6% -$26.4K 0.14% 67
2019
Q4 		$419K Hold
8,725
– – 0.14% 75
2019
Q3 		$295K Buy
8,725
+550
+7% +$23.9K 0.1% 87
2019
Q2 		$368K Hold
8,175
– – 0.15% 67
2019
Q1 		$308K Hold
8,175
– – 0.13% 70
2018
Q4 		$281K Hold
8,175
– – 0.14% 72
2018
Q3 		$384K Hold
8,175
– – 0.18% 66
2018
Q2 		$276K Hold
8,175
– – 0.14% 77
2018
Q1 		$221K Buy
+8,175
New +$207K 0.13% 84
2017
Q1 		– Sell
-431,135
Closed -$4.7M – 100
2016
Q4 		$4.7M Buy
+431,135
New +$4.52M 3.25% 5

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Sicart Associates's PTCT Position: Q2 2026 in Review

Sicart Associates opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 2,745 shares worth $224K. The stake represents 0.05% of the portfolio and ranks #72 among its holdings. This is a return to the name: Sicart Associates previously reported a position in PTCT as recently as Q4 2025.

Sicart Associates first reported a position in PTCT in Q4 2016 and has held it in 25 quarters since. The position peaked at $4.7M in Q4 2016. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Sicart Associates held 2,745 shares of PTC Therapeutics worth $224K as of Q2 2026.
  • PTC Therapeutics was a new Sicart Associates position in Q2 2026.
  • PTC Therapeutics made up 0.05% of Sicart Associates's portfolio in Q2 2026, its #72 holding.
  • Sicart Associates first reported a position in PTC Therapeutics in Q4 2016 and has held it in 25 quarters since.
  • Sicart Associates's PTC Therapeutics position peaked at $4.7M in Q4 2016.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Sicart Associates's 13F filing for Q2 2026, filed 11 Aug 2026.